Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 2
1980 2
1983 1
1985 2
1989 1
1991 4
1992 8
1993 7
1994 6
1995 5
1996 4
1997 4
1998 7
1999 1
2000 4
2001 5
2002 6
2003 7
2004 11
2005 15
2006 8
2007 6
2008 6
2009 16
2010 9
2011 16
2012 20
2013 17
2014 17
2015 16
2016 14
2017 6
2018 10
2019 16
2020 24
2021 26
2022 35
2023 19
2024 25
2025 21
2026 29

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

398 results

Results by year

Filters applied: . Clear all
Page 1
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3.
Levis MJ, Hamadani M, Logan B, Jones RJ, Singh AK, Litzow M, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Ueda Oshima M, Uy GL, Waller EK, Vasu S, Solh M, Mishra A, Muffly L, Kim HJ, Mikesch JH, Najima Y, Onozawa M, Thomson K, Nagler A, Wei AH, Marcucci G, Geller NL, Hasabou N, Delgado D, Rosales M, Hill J, Gill SC, Nuthethi R, King D, Wittsack H, Mendizabal A, Devine SM, Horowitz MM, Chen YB; BMT-CTN 1506/MORPHO Study Investigators. Levis MJ, et al. Among authors: rosales m. J Clin Oncol. 2024 May 20;42(15):1766-1775. doi: 10.1200/JCO.23.02474. Epub 2024 Mar 12. J Clin Oncol. 2024. PMID: 38471061 Free PMC article. Clinical Trial.
Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML.
Levis MJ, Hamadani M, Logan BR, Jones RJ, Singh AK, Litzow MR, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Oshima MU, Uy GL, Waller EK, Vasu S, Solh M, Mishra A, Muffly LS, Kim HJ, Stelljes M, Najima Y, Onozawa M, Thomson K, Nagler A, Wei AH, Marcucci G, Chen C, Hasabou N, Rosales M, Hill J, Gill SC, Nuthethi R, King D, Mendizabal A, Devine SM, Horowitz MM, Chen YB. Levis MJ, et al. Among authors: rosales m. Blood. 2025 May 8;145(19):2138-2148. doi: 10.1182/blood.2024025154. Blood. 2025. PMID: 39775763 Free PMC article. Clinical Trial.
Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer.
Shore ND, Luz MA, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM, Haas GP, Kim CS, Ramirez-Backhaus M, Rannikko A, Kalac M, Sridharan S, Rosales M, Tang Y, Tutrone RF Jr, Venugopal B, Villers A, Woo HH, Wang F, Freedland SJ. Shore ND, et al. Among authors: rosales m. N Engl J Med. 2026 Feb 5;394(6):563-575. doi: 10.1056/NEJMoa2510310. Epub 2025 Oct 19. N Engl J Med. 2026. PMID: 41124201 Clinical Trial.
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.
Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, Sun W, Jalal SI, Shah MA, Metges JP, Garrido M, Golan T, Mandala M, Wainberg ZA, Catenacci DV, Ohtsu A, Shitara K, Geva R, Bleeker J, Ko AH, Ku G, Philip P, Enzinger PC, Bang YJ, Levitan D, Wang J, Rosales M, Dalal RP, Yoon HH. Fuchs CS, et al. Among authors: rosales m. JAMA Oncol. 2018 May 10;4(5):e180013. doi: 10.1001/jamaoncol.2018.0013. Epub 2018 May 10. JAMA Oncol. 2018. PMID: 29543932 Free PMC article. Clinical Trial.
Reply by Authors.
Shore ND, Gleave M, De Giorgi U, Rannikko A, Pieczonka CM, Sridharan S, Brasso K, Woo HH, Gómez Caamaño A, Saranchuk JW, Nordquist LT, Ferreira U, Tang Y, Rosbrook B, Haas GP, Rosales M, Zohren F, Tarazi J, Freedland SJ. Shore ND, et al. Among authors: rosales m. J Urol. 2026 May;215(5):524-525. doi: 10.1097/JU.0000000000004962. Epub 2026 Feb 6. J Urol. 2026. PMID: 41650342 No abstract available.
Reply by Authors.
Shore ND, Gleave M, De Giorgi U, Rannikko A, Pieczonka CM, Sridharan S, Brasso K, Woo HH, Gómez Caamaño A, Saranchuk JW, Nordquist LT, Ferreira U, Tang Y, Rosbrook B, Haas GP, Rosales M, Zohren F, Tarazi J, Freedland SJ. Shore ND, et al. Among authors: rosales m. J Urol. 2026 May;215(5):523. doi: 10.1097/JU.0000000000004961. Epub 2026 Feb 6. J Urol. 2026. PMID: 41650344 No abstract available.
Impact of transplant conditioning, NPM1 mutations, and measurable residual disease in FLT3-ITD acute myeloid leukemia.
Levis MJ, Hamadani M, Logan BR, Jones RJ, Singh AK, Litzow MR, Wingard JR, Papadopoulos EB, Perl AE, Soiffer RJ, Ustun C, Oshima MU, Uy GL, Waller EK, Vasu S, Solh M, Mishra A, Muffly LS, Kim HJ, Stelljes M, Najima Y, Onozawa M, Thomson K, Chen C, Hasabou N, Rosales M, Hill JE, Gill SC, Nuthethi R, King D, Mendizabal A, Devine SM, Horowitz MM, Chen YB. Levis MJ, et al. Among authors: rosales m. Blood Adv. 2025 Oct 28;9(20):5123-5133. doi: 10.1182/bloodadvances.2025016306. Blood Adv. 2025. PMID: 40590852 Free PMC article. Clinical Trial.
Margetuximab in HER2-positive metastatic breast cancer.
Gradishar WJ, O'Regan R, Rimawi MF, Nordstrom JL, Rosales MK, Rugo HS. Gradishar WJ, et al. Among authors: rosales mk. Future Oncol. 2023 May;19(16):1099-1112. doi: 10.2217/fon-2022-1040. Epub 2023 May 12. Future Oncol. 2023. PMID: 37170847 Free article. Review.
398 results